DUBLIN–(BUSINESS WIRE)–The “Vision Care Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023” report has been added to ResearchAndMarkets.com’s offering. According to the report, the global vision care market reache…
Category: Business
Aerie Pharmaceuticals Announces Appointment of Scott Laranjo as Director, Marketing, Roclatan™
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Scott Laranjo as Director, Marketing, RoclatanTM, reporting to Deanne Melloy, Aerie’s Vice President of Marketing. Mr. Laranjo will direct future marketing activities associated w
SERI Lugano: FDA wählt ParaCel Riboflavin für die „Epi-on“-Hornhautquervernetzung zur Behandlung von Keratokonus
LUGANO, Schweiz–(BUSINESS WIRE)–Wie das Switzerland Eye Research Institute bekanntgab, wählte die FDA aus zahlreichen Alternativen die als ParaCel bekannte, bahnbrechende transepitheliale Riboflavinformulierung für die Behandlung von Patienten mit progressivem Keratokonus. ParaCel basiert auf den Resultaten der Forschungsarbeit von Dr. Pinelli, dem Gründer und CEO des Instituts. AVEDRO, Inc., Waltham, Mass. hatte 2011 alle Rechte am geistigen Eigentum erworben, die das Unternehmen zur Herstel
SERI Lugano: la riboflavina ParaCel scelta dalla FDA per il cross-linking epi-on per cheratocono
LUGANO, Svizzera–(BUSINESS WIRE)–Lo Switzerland Eye Research Institute ha annunciato che, secondo quanto riportato da un comunicato stampa, la rivoluzionaria formulazione a base di ribloflavina transepiteliale nota come ParaCel, frutto della ricerca dell’amministratore delegato e fondatore dell’istituto, il Dr. Roberto Pinelli, è stata scelta dalla FDA insieme a diverse altre per un protocollo di cross-linking del collagene corneale epi-on (senza asportazione dell’epitelio corneale) per i paz
SERI Lugano: ParaCel riboflavine geselecteerd door FDA voor epi-on crosslinking voor keratoconus
LUGANO, Zwitserland–(BUSINESS WIRE)–Het Switzerland Eye Research Institute heeft aangekondigd dat de doorbraakformulering voor transepitheliale riboflavine, bekend als ParaCel, en op basis van het onderzoek van haar CEO en oprichter Roberto Pinelli, MD, door de FDA uit vele inzendingen is geselecteerd voor een behandelprotocol voor epithelial-on corneale collageen crosslinking voor patiënten met progressieve keratoconus, volgens een persbericht. Alle intellectuele eigendomsrechten voor het pr
SERI Lugano : La riboflavine ParaCel est sélectionnée par la FDA pour être utilisée dans le cadre du crosslinking epi-on pour le kératocône
LUGANO, Suisse–(BUSINESS WIRE)–Le Switzerland Eye Research Institute a annoncé que la formulation de riboflavine transépithéliale novatrice, connue sous le nom de ParaCel et basée sur la recherche de son président-directeur général et fondateur Roberto Pinelli, MD, avait été sélectionnée parmi un grand nombre d’autres formulations par la FDA (Food and Drug Administration – Agence américaine de contrôle des produits alimentaires et médicamenteux) pour un protocole de crosslinking (CXL) (réticu
LENSAR® Laser System Receives FDA Clearance to Perform Corneal Pockets and Flaps for Corneal Inlay Procedures
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR receives FDA clearance for LENSAR Laser System with Streamline IV to perform corneal pockets and flaps for corneal inlay procedures.
Multiple Surgeon Presentations to Include Glaukos Technologies at 2018 American Society of Cataract and Refractive Surgery
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, …
The Global Ophthalmic Surgical Instruments Market is Estimated to Reach USD 11.18 Billion by 2022 from USD 8.36 Billion in 2017, at a CAGR of 6.0% – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmic Surgical Instruments Market – Global Forecast to 2022” report has been added to ResearchAndMarkets.com’s offering. The global ophthalmic surgical instruments market is expected to reach USD 11.18 billion by 2022…
Top Student Inventors Awarded Lemelson-MIT Student Prize
CAMBRIDGE, Mass.–(BUSINESS WIRE)–#InvenTeams–Following a nationwide search for the most inventive college students, the Lemelson-MIT Program today announced the winners of the 2018 Lemelson-MIT Student Prize. The Program awarded a total of $80,000 i…
Avedro Celebrates 10 Year Anniversary
WALTHAM, Mass.–(BUSINESS WIRE)–Avedro, Inc. today announced that it has reached a milestone, celebrating 10 years of scientific research, innovation and business. Since its founding in 2008, Avedro has grown from a small R&D company to an internationally recognized ophthalmic pharmaceutical and medical device company and the world leader in corneal remodeling. “Avedro’s 10-year journey began with the exploration of using microwave technology to reshape the cornea,” said Reza Zadno, PhD, C
Singapore Eyewear Market 2017-2021 by Type, Sunglasses & Eyeglasses, and Sales Channel – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Singapore Eyewear Market by Type (Spectacles & Contact Lenses), By Sunglasses and Eyeglasses and by Sales Channel – Outlook to 2021” report has been added to ResearchAndMarkets.com’s offering. The report includes the government initiatives and regulations in Singapore eyewear market, competitive landscape and company profiles for major players in the eyewear market. The report provides detailed overview on the general features of eyewear in the country and futu
Malaysia Eyewear Market Analysis & Outlook 2011-2021 – Key Players are Luxottica, Johnson & Johnson and Hoya Corp – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Malaysia Eyewear Market By Type (Spectacles and Contact Lenses), By Sunglasses and Eyeglasses and By Sales Channel – Outlook to 2021” report has been added to ResearchAndMarkets.com’s offering. The report covers market siz…
Kala Pharmaceuticals Appoints Eric Trachtenberg as General Counsel and Corporate Secretary
WALTHAM, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals announces the appointment of Eric Trachtenberg as General Counsel and Corporate Secretary.
Europe Minimally Invasive Glaucoma Surgery Devices (Stents, Shunts, and Others) Market Analysis 2017-2023 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Europe Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Analysis (2017-2023)” report has been added to ResearchAndMarkets.com’s offering. The Europe Minimally Invasive Glaucoma Surgery (MIGS) Devices Market is exp…
Glaucoma Market Spotlight 2018-2028 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Market Spotlight: Glaucoma” report has been added to ResearchAndMarkets.com’s offering. This Market Spotlight report covers the Glaucoma market, comprising key pipeline and marketed drugs, clinical trials, upcoming and reg…
APAC Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Report 2018-2023 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Asia Pacific Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Analysis (2017-2023)” report has been added to ResearchAndMarkets.com’s offering. The Asia Pacific Minimally Invasive Glaucoma Surgery (MIGS) Devices M…
CareCloud to Host First User Summit in Miami, September 7-9, 2018
MIAMI–(BUSINESS WIRE)–#RCM–CareCloud, the platform for high-performing medical groups today announced that its first user summit – hosting the country’s fastest growing physician practices – will be held at the Hilton Miami Downtown. Beginning September 7, CloudUP ’18, will inspire practice leaders to use technology in new ways to modernize the patient experience and to improve every aspect of running a practice in today’s competitive environment. During CloudUP ’18, hundreds of tech forward pract
Colonial Life launches dental and vision coverage
COLUMBIA, S.C.–(BUSINESS WIRE)–Colonial Life launches new dental and vision coverage. Dental and vision benefits help maintain and promote overall health.
Castle Biosciences Announces Inclusion of DecisionDx-UM Prognostic Test in New NCCN Guidelines for Uveal Melanoma
FRIENDSWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc., today announced that the National Comprehensive Cancer Network (NCCN) has included the DecisionDx®-UM gene expression profile (GEP) test class results in their new clinical practice guidelines for uveal melanoma. These recommendations, released on March 15, 2018, are the first-ever NCCN guidelines for uveal melanoma, and their publication is an important milestone in the care of patients with this rare eye cancer. The new guidelines